Application of DNA Methylation in Our Body: Mechanisms and Roles
By Dr. Zubair Khalid, DVM, MS, PhD ·
Introduction to DNA Methylation
DNA methylation is a covalent chemical modification in which a methyl group (–CH₃) is transferred to the fifth carbon position of the cytosine pyrimidine ring, producing 5-methylcytosine (5-mC). This reaction occurs almost exclusively at cytosine residues that are followed by guanine in the 5′→3′ direction—the so-called CpG dinucleotide. The transfer is catalyzed by a family of enzymes known as DNA methyltransferases (DNMTs), using S-adenosylmethionine (SAM) as the methyl donor. In adult somatic human cells, approximately 70–80% of all CpG dinucleotides are methylated, yet the distribution is far from uniform across the genome.
The Epigenetic Mark
DNA methylation is the most extensively studied epigenetic mark—a heritable, reversible modification that alters gene expression without changing the underlying DNA sequence. Unlike genetic mutations, which permanently alter the nucleotide sequence, methylation patterns are dynamic and can be remodeled in response to developmental cues, environmental stimuli, and pathological states. The functional consequence of methylation depends entirely on its genomic context: methylation at gene promoters generally correlates with transcriptional repression, whereas methylation within gene bodies is often associated with active transcription. This context-dependence is a recurring theme throughout this article, and it is a common source of confusion for students first encountering the field.
Genomic Distribution
The human genome contains roughly 28 million CpG dinucleotides, but they are not evenly distributed. CpG islands—regions of 300–3,000 base pairs with a high GC content and a CpG density at least 50% greater than the genome average—are found in the promoter regions of approximately 60–70% of human genes. In normal cells, these promoter-associated CpG islands are almost always unmethylated, regardless of whether the gene is active or silent. Instead, methylation is concentrated in intergenic regions, repetitive elements (such as LINE-1 and Alu retrotransposons), and gene bodies. This pattern is not accidental: methylation of repetitive elements is a critical genome-defense mechanism that prevents transposon mobilization and maintains chromosomal stability. Loss of methylation at these elements is observed in many cancers and is associated with genomic instability.
The Enzymatic Machinery of DNA Methylation
The establishment and maintenance of DNA methylation patterns require a coordinated system of enzymes that write, maintain, and erase the mark. Disruption of any component of this machinery has profound developmental and pathological consequences.
Writers: DNA Methyltransferases
Three catalytically active DNA methyltransferases operate in mammals, each with distinct roles.
DNMT1 is the maintenance methyltransferase. During DNA replication, the parental strand retains its methylation pattern, but the newly synthesized daughter strand is initially unmethylated. DNMT1 recognizes these hemimethylated CpG sites—where the cytosine on one strand is methylated but its partner on the complementary strand is not—and methylates the nascent strand to restore the symmetric pattern. This enzyme is recruited to replication foci through its interaction with proliferating cell nuclear antigen (PCNA) and the accessory protein UHRF1, which specifically binds hemimethylated CpG sites. The efficiency of this maintenance process is remarkable: without DNMT1, cells lose approximately 95% of their methylation over successive divisions.
DNMT3A and DNMT3B are the de novo methyltransferases. Unlike DNMT1, they do not require a pre-existing methylation pattern and can methylate previously unmethylated CpG sites. These enzymes are essential during embryogenesis, where they establish the genome-wide methylation landscape shortly after implantation. DNMT3A and DNMT3B have distinct but overlapping target preferences; DNMT3B is particularly important for methylating the CpG islands on the inactive X chromosome and pericentromeric repeats. Mutations in DNMT3B cause immunodeficiency, centromeric instability, and facial anomalies (ICF) syndrome, underscoring its non-redundant role. DNMT3L, a catalytically inactive homolog, acts as a regulatory cofactor for DNMT3A/3B, particularly in germ cells.
Erasers: TET Enzymes
For decades, DNA methylation was considered irreversible, with passive dilution through cell division as the only removal mechanism. The discovery of the ten-eleven translocation (TET) family of enzymes—TET1, TET2, and TET3—revolutionized this view. TET enzymes catalyze the sequential oxidation of 5-methylcytosine to 5-hydroxymethylcytosine (5-hmC), then to 5-formylcytosine (5-fC), and finally to 5-carboxylcytosine (5-caC). These oxidized derivatives can be recognized and excised by thymine DNA glycosylase (TDG), initiating base excision repair that replaces the modified cytosine with an unmethylated cytosine. This process, termed active demethylation, allows rapid, replication-independent removal of methylation marks.
TET2 is particularly notable because it is one of the most frequently mutated genes in myeloid malignancies, including acute myeloid leukemia and myelodysplastic syndromes. Loss of TET2 function leads to hypermethylation at enhancer regions and impaired hematopoietic differentiation. The TET enzymes require α-ketoglutarate, iron (Fe²⁺), and oxygen as cofactors, making them sensitive to metabolic perturbations—a link between cellular metabolism and epigenetic regulation that has therapeutic implications.
How DNA Methylation Regulates Gene Expression
The relationship between DNA methylation and transcription is mediated through two principal mechanisms: direct interference with transcription factor binding and indirect recruitment of methyl-CpG-binding proteins that remodel chromatin.
Promoter Methylation and Silencing
When CpG islands in promoter regions become methylated—an event that occurs at specific loci during development and aberrantly in cancer—transcription is typically repressed. The mechanisms are multifaceted. First, methylation of CpG sites within transcription factor recognition sequences can physically block the binding of activators. For example, the binding of specificity protein 1 (Sp1) and c-Myc to their cognate motifs is methylation-sensitive. Second, and more pervasively, methylated CpG sites serve as docking platforms for a family of proteins containing a methyl-CpG-binding domain (MBD), including MeCP2, MBD1, MBD2, and MBD3. MeCP2, the protein mutated in Rett syndrome, recruits the Sin3A/histone deacetylase (HDAC) complex, leading to deacetylation of histone tails and compaction of chromatin into a transcriptionally repressive state. MBD2 similarly recruits the Nucleosome Remodeling and Deacetylase (NuRD) complex, coupling histone deacetylation with ATP-dependent chromatin remodeling.
The result is a self-reinforcing repressive state. Once established, promoter methylation leads to histone H3 lysine 9 dimethylation (H3K9me2) and H3 lysine 27 trimethylation (H3K27me3), which in turn recruit additional methyltransferases that maintain the methylation pattern. This positive feedback loop explains why promoter methylation is a stable, heritable silencing mechanism—one that is difficult to reverse spontaneously. For a detailed mechanistic discussion of how methylation at promoters silences genes, see DNA Methylation Decrease Gene Expression.
Enhancer Methylation and Gene Activity
The role of methylation at enhancers is more nuanced than at promoters. Active enhancers are typically characterized by low DNA methylation, and the binding of lineage-determining transcription factors such as FOXA1 and PU.1 is required to maintain these regions in a hypomethylated state. Conversely, methylation of enhancer regions is associated with loss of enhancer activity and reduced expression of target genes. This is particularly evident during cellular differentiation, where enhancer methylation changes dynamically and often precedes changes in the expression of nearby genes.
However, the relationship is not strictly binary. Some transcription factors, such as CTCF, bind to methylated DNA in a context-dependent manner. CTCF is a chromatin organizer that establishes boundaries between topologically associating domains (TADs). Its binding at the H19/IGF2 imprinted locus is methylation-sensitive: CTCF binds only to the unmethylated maternal allele, creating a chromatin boundary that blocks access of the IGF2 enhancer to the promoter. On the paternal allele, where the CTCF binding site is methylated, CTCF cannot bind, and the enhancer activates IGF2 expression. This example illustrates that methylation can either repress or permit gene expression depending on the specific regulatory element and the proteins that recognize it. For a broader discussion of contexts in which methylation is associated with increased transcription, refer to DNA Methylation Increase Gene Expression.
DNA Methylation in Development and Cell Differentiation
The mammalian life cycle is characterized by two global waves of DNA methylation reprogramming. After fertilization, the paternal genome undergoes rapid active demethylation within hours, while the maternal genome is demethylated more slowly, largely through passive dilution. This erasure resets the epigenome to a pluripotent state, allowing the zygote to give rise to all cell types. A second wave of demethylation occurs in primordial germ cells, which is essential for erasing parental imprints and establishing the potential for sex-specific imprinting in the next generation.
Following implantation, de novo methylation by DNMT3A and DNMT3B re-establishes genome-wide methylation patterns. This is followed by cell-type-specific methylation changes that lock in lineage commitment. As cells differentiate, they acquire a methylation signature that reflects their developmental history and identity. For example, hepatocytes and neurons differ in the methylation status of thousands of CpG sites, many of which are located at enhancers that control tissue-specific gene expression.
Genomic Imprinting
Genomic imprinting is an epigenetic phenomenon in which a subset of genes is expressed exclusively from one parental allele. Approximately 100–200 imprinted genes are known in humans, and most are organized into clusters regulated by imprinting control regions (ICRs). These ICRs are differentially methylated regions (DMRs): the ICR is methylated on one parental allele and unmethylated on the other. The methylation mark is established in the germline and maintained throughout somatic development, making imprinting one of the most stable forms of epigenetic regulation.
The best-characterized example is the H19/IGF2 locus on chromosome 11p15.5. The ICR between these two genes is methylated on the paternal allele, which prevents CTCF binding and allows IGF2 expression. On the maternal allele, the ICR is unmethylated, CTCF binds, and a chromatin boundary forms that silences IGF2 while permitting H19 expression. Loss of imprinting at this locus—where both alleles express IGF2—is observed in Beckwith-Wiedemann syndrome and in several cancers. The clinical importance of imprinting is further underscored by Prader-Willi and Angelman syndromes, which result from deletions or uniparental disomy affecting the imprinted region on chromosome 15q11-q13. For a comprehensive overview, see Genomic Imprinting.
X-Chromosome Inactivation
In female mammals, one of the two X chromosomes is transcriptionally silenced to achieve dosage compensation between XX females and XY males. This process, called X-chromosome inactivation, is initiated by the long non-coding RNA XIST, which coats the future inactive X chromosome and recruits chromatin-modifying complexes. DNA methylation plays a critical role in the maintenance of the inactive state: the promoter of XIST itself is methylated on the active X chromosome (preventing XIST expression), while many CpG islands across the inactive X become densely methylated. This methylation is established after the initial silencing and serves to lock in the inactive state, making it heritable through subsequent cell divisions. The inactive X chromosome is also enriched for H3K27me3 and depleted of histone acetylation, illustrating the cooperation between DNA methylation and histone modifications in maintaining a stable silenced state.
DNA Methylation in Aging and Disease
DNA methylation patterns are not static throughout life. They drift with age, and this drift is both predictable and informative. Moreover, aberrant methylation is a hallmark of numerous diseases, most notably cancer.
Epigenetic Clocks
The observation that methylation at specific CpG sites changes reproducibly with age has led to the development of epigenetic clocks—mathematical models that predict biological age from methylation data. The most widely used is the Horvath clock, which is based on methylation levels at 353 CpG sites and can estimate age across multiple tissue types with a median error of less than 3.5 years. The Hannum clock, developed for blood, uses 71 CpG sites. These clocks measure not chronological age but biological age—the cumulative wear and tear on the organism. Individuals with a biological age higher than their chronological age (epigenetic age acceleration) have an increased risk of all-cause mortality, cardiovascular disease, and cancer.
The mechanisms driving age-related methylation changes are incompletely understood but likely involve the gradual erosion of methylation at CpG islands (hypomethylation) and the accumulation of methylation at others (hypermethylation). Age-related hypomethylation is particularly pronounced at repetitive elements, which may contribute to genomic instability. Conversely, hypermethylation often occurs at Polycomb target genes—genes that are developmentally regulated and marked by H3K27me3 in embryonic stem cells. These changes are thought to reflect the declining fidelity of the maintenance methylation machinery and the cumulative effects of environmental exposures.
Methylation in Cancer
Cancer is the disease in which aberrant DNA methylation is best characterized, and the patterns are paradoxical. Two opposing phenomena occur simultaneously: global hypomethylation and focal hypermethylation.
Global hypomethylation, affecting primarily repetitive elements and gene bodies, is one of the earliest events in tumorigenesis. Loss of methylation at LINE-1 and Alu elements is associated with chromosomal instability, reactivation of transposons, and loss of genomic integrity. Hypomethylation can also lead to aberrant activation of oncogenes; for example, hypomethylation of the promoter of the melanoma-associated antigen (MAGE) family genes leads to their inappropriate expression in various cancers.
Simultaneously, tumor suppressor genes undergo promoter CpG island hypermethylation, which silences them in a manner functionally equivalent to mutation or deletion. Classic examples include the cell cycle regulator CDKN2A (encoding p16^INK4A^), the DNA repair gene MLH1, and the apoptosis regulator DAPK1. Hypermethylation of MLH1 is particularly instructive: it occurs in approximately 15–20% of sporadic colorectal cancers and results in microsatellite instability, a phenotype identical to that caused by MLH1 mutations in Lynch syndrome. The detection of MLH1 promoter methylation has diagnostic and prognostic value, as these tumors respond differently to chemotherapy.
The cancer methylome is not random. Specific CpG islands are preferentially targeted for hypermethylation, and this targeting is influenced by the presence of Polycomb repressive complexes and the local chromatin environment. The concept of a CpG island methylator phenotype (CIMP) has been proposed to describe a subset of tumors with particularly extensive promoter methylation, and CIMP is associated with distinct clinical features in colorectal cancer and glioblastoma.
Methods to Study DNA Methylation
Studying DNA methylation requires methods that can distinguish 5-methylcytosine from cytosine with single-base resolution. The gold-standard approach exploits the differential reactivity of these two bases to sodium bisulfite.
Bisulfite Conversion
Treatment of denatured DNA with sodium bisulfite under acidic conditions deaminates unmethylated cytosines to uracil, while 5-methylcytosine is resistant to deamination and remains as cytosine. After PCR amplification, uracils are amplified as thymines, whereas methylated cytosines are amplified as cytosines. The methylation status of each CpG site is then determined by comparing the bisulfite-converted sequence to the reference genome.
The standard bisulfite conversion protocol uses 3 M sodium bisulfite at pH 5.0, with incubation at 50°C for 4–16 hours. The reaction is harsh and degrades DNA, so typical input amounts are 500 ng to 2 µg of genomic DNA. Following conversion, desulfonation is achieved by alkaline treatment (pH 13) at 37°C for 15 minutes, and the DNA is purified by column chromatography.
Next-Generation Sequencing Approaches
Bisulfite conversion can be coupled with various sequencing platforms. Whole-genome bisulfite sequencing (WGBS) provides genome-wide coverage at single-base resolution but is expensive and computationally demanding. Reduced representation bisulfite sequencing (RRBS) enriches for CpG-dense regions by digesting genomic DNA with a restriction enzyme such as MspI (which cuts at CCGG sites), followed by size selection and bisulfite sequencing. RRBS covers approximately 3–5% of CpG sites but is biased toward CpG islands and promoters, making it a cost-effective choice for many studies.
For targeted analysis, bisulfite-specific PCR (BSP) followed by Sanger sequencing or next-generation sequencing allows interrogation of specific loci. Methylation-specific PCR (MSP) is a qualitative method that uses primers designed to discriminate between methylated and unmethylated alleles after bisulfite conversion. MSP is rapid and sensitive but provides no quantitative information and is prone to false positives if the bisulfite conversion is incomplete.
Array-based methods, such as the Illumina Infinium MethylationEPIC BeadChip, interrogate methylation at over 850,000 CpG sites without sequencing. These arrays use two bead types per CpG site—one matching the unmethylated and one the methylated sequence—and measure the ratio of fluorescence signals. The EPIC array is widely used in epidemiological studies because it offers a favorable balance of coverage, cost, and throughput, though it cannot detect methylation at CpG sites not represented on the array.
A critical quality control step in all bisulfite-based methods is verifying conversion efficiency. This is typically done by including unmethylated DNA (e.g., lambda phage DNA) as a spike-in control and calculating the conversion rate, which should exceed 98%. Incomplete conversion leads to false-positive methylation calls, a common pitfall in student experiments.
Therapeutic Applications and Clinical Implications
The reversibility of DNA methylation makes it an attractive therapeutic target. Unlike genetic mutations, which are permanent, methylation marks can be pharmacologically manipulated.
Epigenetic Drugs
Two nucleoside analogs—5-azacytidine (azacitidine) and 5-aza-2′-deoxycytidine (decitabine)—are approved by regulatory agencies for the treatment of myelodysplastic syndromes and acute myeloid leukemia. These drugs are incorporated into DNA during replication, where they covalently trap DNMT1, leading to its degradation and the passive loss of methylation in daughter cells. The result is reactivation of silenced tumor suppressor genes and differentiation or apoptosis of leukemic cells.
The clinical use of these agents requires careful dosing. At high doses, they are cytotoxic and cause significant myelosuppression. At low doses, they are demethylating and can be administered over multiple cycles. Typical regimens use 75 mg/m² daily for 7 days (azacitidine) or 20 mg/m² daily for 5 days (decitabine), repeated every 4 weeks. Response rates in myelodysplastic syndromes are approximately 40–50%, and these drugs are the standard of care for higher-risk patients.
A significant limitation of nucleoside analogs is their lack of locus specificity: they demethylate the entire genome, which can reactivate oncogenes or transposable elements. This has motivated the development of more targeted approaches, including antisense oligonucleotides that recruit DNMTs to specific loci and CRISPR-dCas9 systems fused to TET enzymes or DNMTs for targeted demethylation or methylation, respectively. These tools are in preclinical development but hold promise for locus-specific epigenetic editing.
Diagnostic Biomarkers
DNA methylation is an excellent biomarker because it is stable in biological fluids, detectable in small quantities, and often altered early in disease. Methylated DNA can be detected in circulating cell-free DNA (cfDNA) in plasma, making liquid biopsies feasible.
The best-established example is the detection of methylated SEPT9 in plasma for colorectal cancer screening. The Epi proColon test detects SEPT9 promoter methylation by real-time PCR and has a sensitivity of approximately 70% for colorectal cancer, with a specificity of 90%. Similarly, the detection of methylated GSTP1 in urine or plasma is used to aid in the diagnosis of prostate cancer. In gliomas, the methylation status of the MGMT promoter predicts response to temozolomide chemotherapy: patients with methylated MGMT have longer survival because the DNA repair enzyme is silenced, making tumor cells more sensitive to alkylating agents.
The field of epigenetic biomarkers is expanding rapidly, with multi-cancer early detection tests that analyze methylation patterns in cfDNA to identify the presence and tissue of origin of tumors. These tests use machine learning algorithms trained on large cohorts of cancer patients and healthy controls, and they represent a convergence of epigenetics, genomics, and computational biology.
Common Pitfalls and Misconceptions
Students frequently encounter several conceptual errors when learning about DNA methylation. Recognizing these pitfalls early will prevent confusion in exams and in the laboratory.
Methylation vs. Histone Modifications
DNA methylation and histone methylation are distinct modifications with different writers, erasers, and genomic distributions. DNA methylation occurs on cytosine bases in DNA and is catalyzed by DNMTs. Histone methylation occurs on lysine or arginine residues of histone proteins and is catalyzed by histone methyltransferases such as EZH2 (for H3K27me3) and SUV39H1 (for H3K9me3). The two systems interact—histone methylation can recruit DNMTs and vice versa—but they are not interchangeable. A common exam error is to state that DNA methylation occurs on histones or that histone methylation occurs on DNA. For a detailed comparison, see Histone Methylation.
Assuming All Methylation Causes Silencing
The statement "DNA methylation silences genes" is an oversimplification. Promoter CpG island methylation is generally repressive, but methylation in gene bodies is associated with active transcription. Methylation at enhancers can be either permissive or repressive depending on the transcription factors involved. Furthermore, methylation at CTCF binding sites can actually promote gene expression by preventing boundary formation. The functional outcome of methylation is determined by genomic context, the density of CpG sites, and the proteins that recognize the methyl mark. Always specify the genomic location when discussing the effect of methylation.
Overlooking the Role of Methylation in Gene Bodies
Gene body methylation—methylation of CpG sites within the transcribed region of genes—is positively correlated with gene expression levels. This is the opposite of promoter methylation. Several hypotheses explain this association: gene body methylation may suppress spurious transcription initiation from cryptic promoters within the gene, or it may be a byproduct of transcription-associated processes. Regardless of the mechanism, students should remember that gene body methylation is a marker of active genes, not silenced ones.
Confusing Maintenance and De Novo Methylation
DNMT1 is the maintenance methyltransferase, responsible for copying methylation patterns during replication. DNMT3A and DNMT3B are the de novo methyltransferases, responsible for establishing new patterns. A common error is to state that DNMT1 establishes methylation patterns during development or that DNMT3 enzymes maintain methylation during replication. The distinction matters because mutations in these enzymes have different consequences: DNMT1 knockout is embryonic lethal due to global loss of methylation, while DNMT3B mutations cause ICF syndrome with a more restricted phenotype.
Assuming Methylation Is Irreversible
The discovery of TET enzymes and active demethylation has overturned the view that DNA methylation is a permanent mark. Demethylation can occur passively (through failure of maintenance methylation during replication) or actively (through TET-mediated oxidation followed by base excision repair). This reversibility is the basis for epigenetic therapy and for the dynamic regulation of methylation during development.
Neglecting the Role of Methylation in Non-CpG Contexts
While CpG methylation predominates in somatic cells, non-CpG methylation (at CHG and CHH sites, where H is A, C, or T) is abundant in embryonic stem cells and in the brain. In these contexts, DNMT3A and DNMT3B catalyze non-CpG methylation, and its function is still being elucidated. Students should be aware that DNA Methylation Only Occur on Cytosine is technically accurate—the modification is always on cytosine—but the flanking sequence context matters.
Frequently Asked Questions
What is DNA methylation and why is it important?
DNA methylation is the covalent addition of a methyl group to the fifth carbon of cytosine, producing 5-methylcytosine. It is catalyzed by DNA methyltransferases using S-adenosylmethionine as the methyl donor. DNA methylation is important because it regulates gene expression, maintains genome stability by silencing transposable elements, establishes genomic imprinting, mediates X-chromosome inactivation, and contributes to cellular differentiation. Aberrant methylation is implicated in cancer, neurological disorders, and aging.
How does DNA methylation affect gene expression?
The effect depends on genomic context. Methylation at promoter CpG islands generally represses transcription by blocking transcription factor binding and recruiting methyl-CpG-binding proteins such as MeCP2, which bring in histone deacetylases and chromatin remodeling complexes. Methylation at enhancers typically reduces enhancer activity. In contrast, gene body methylation is associated with active transcription. Methylation at CTCF binding sites can disrupt chromatin boundaries and thereby alter gene expression in either direction.
What enzymes add and remove DNA methylation?
DNA methyltransferases add methylation: DNMT1 maintains existing patterns during replication, while DNMT3A and DNMT3B establish new patterns. TET enzymes (TET1, TET2, TET3) remove methylation by oxidizing 5-methylcytosine to 5-hydroxymethylcytosine and further oxidized derivatives, which are then excised by thymine DNA glycosylase and repaired to unmethylated cytosine. Passive demethylation can also occur when DNMT1 fails to maintain methylation during successive rounds of replication.
What is genomic imprinting?
Genomic imprinting is an epigenetic phenomenon in which a subset of genes is expressed from only one parental allele. Imprinted genes are regulated by imprinting control regions that are differentially methylated in the maternal and paternal germlines. This methylation is established during gametogenesis and maintained in somatic cells. Imprinting disorders include Prader-Willi syndrome, Angelman syndrome, and Beckwith-Wiedemann syndrome.
How is DNA methylation related to cancer?
Cancer cells exhibit two opposing methylation abnormalities: global hypomethylation and focal hypermethylation. Global hypomethylation, particularly at repetitive elements, contributes to genomic instability. Focal hypermethylation at promoter CpG islands silences tumor suppressor genes such as CDKN2A, MLH1, and MGMT. These changes occur early in tumorigenesis and can be detected in circulating cell-free DNA, making them valuable biomarkers for cancer diagnosis and prognosis.
What is the epigenetic clock?
The epigenetic clock is a mathematical model that predicts biological age from DNA methylation levels at a defined set of CpG sites. The Horvath clock uses 353 CpG sites and is applicable across tissues; the Hannum clock uses 71 sites and is optimized for blood. Epigenetic age acceleration—where predicted age exceeds chronological age—is associated with increased mortality risk and age-related diseases.
How is DNA methylation detected experimentally?
The most common approach is bisulfite conversion, which deaminates unmethylated cytosines to uracil while leaving 5-methylcytosine intact. After PCR, the methylation status is determined by sequencing (WGBS, RRBS, targeted bisulfite PCR) or by methylation-specific PCR. Array-based methods such as the Illumina MethylationEPIC BeadChip interrogate hundreds of thousands of CpG sites without sequencing. All methods require careful quality control, particularly verification of bisulfite conversion efficiency.
Can DNA methylation be reversed?
Yes. Active demethylation is catalyzed by TET enzymes, which oxidize 5-methylcytosine and initiate base excision repair. Passive demethylation occurs when maintenance methylation fails during replication. Pharmacologically, nucleoside analogs such as 5-azacytidine and decitabine inhibit DNMT1, leading to genome-wide demethylation. These drugs are approved for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Key Takeaways
- DNA methylation is the covalent addition of a methyl group to cytosine, producing 5-methylcytosine, and occurs predominantly at CpG dinucleotides.
- DNMT1 maintains methylation patterns during replication, while DNMT3A and DNMT3B establish new patterns; TET enzymes initiate active demethylation.
- The effect of methylation on gene expression is context-dependent: promoter methylation generally silences, gene body methylation correlates with activity, and enhancer methylation typically reduces activity.
- DNA methylation is essential for genomic imprinting, X-chromosome inactivation, silencing of transposable elements, and cell-type-specific gene regulation during development.
- Aberrant methylation—global hypomethylation and focal hypermethylation—is a hallmark of cancer and contributes to tumor suppressor silencing and genomic instability.
- Methylation patterns change predictably with age, forming the basis of epigenetic clocks that estimate biological age and predict disease risk.
- DNA methylation is reversible and targetable: demethylating agents are approved cancer therapies, and methylated DNA in body fluids serves as a diagnostic biomarker.
- Bisulfite conversion followed by sequencing or array hybridization is the standard approach for methylation analysis, but requires rigorous quality control to avoid false positives.